60 Degrees PharmaceuticalsSXTP +0.90%44 Quick Ratio is 2.85 as of Mar. 2026, which is 19% above its 10-year median of 2.39. GuruFocus rates SXTP with a GF Score™ of 44/100 and a GF Value™ of $2.07 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 1,417 Biotechnology companies, 60 Degrees Pharmaceuticals ranks worse than 57.16% on this metric.
60 Degrees Pharmaceuticals has a quick ratio of 2.85. It generally indicates good short-term financial strength.
The historical rank and industry rank for 60 Degrees Pharmaceuticals's Quick Ratio or its related term are showing as below:
SXTP'
s Quick Ratio Range Over the Past 10 Years
Min: 0.02 Med: 2.39 Max: 6.77
Current: 2.85
During the past 6 years, 60 Degrees Pharmaceuticals's highest Quick Ratio was 6.77. The lowest was 0.02. And the median was 2.39.
SXTP's Quick Ratio is ranked worse than 57.16% of 1417
companies
in the Biotechnology industry
Industry Median: 3.6
vs SXTP: 2.85
60 Degrees Pharmaceuticals (NAS:SXTP) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
60 Degrees Pharmaceuticals Quick Ratio Related Terms
60 Degrees Pharmaceuticals Quick Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, 60 Degrees Pharmaceuticals's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
60 Degrees Pharmaceuticals Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, 60 Degrees Pharmaceuticals's Quick Ratio distribution charts can be found below:
* The bar in red indicates where 60 Degrees Pharmaceuticals's Quick Ratio falls into.
60 Degrees Pharmaceuticals Quick Ratio Calculation
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
60 Degrees Pharmaceuticals (SXTP) has a Quick Ratio of 2.85 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on 60 Degrees Pharmaceuticals and its competitors. This is 19% above median its historical median of 2.39. Over the past decade, 60 Degrees Pharmaceuticals' Quick Ratio has ranged from 0.02 to 6.77. According to the industry distribution chart, 60 Degrees Pharmaceuticals ranks #810 out of 1417 companies in the Biotechnology industry, placing it in the top 57.2%.
Is 60 Degrees Pharmaceuticals' Quick Ratio too high?
60 Degrees Pharmaceuticals' current Quick Ratio of 2.85 is 19% above median its 10-year median of 2.39. Over the past 10 years, this metric has ranged from a low of 0.02 to a high of 6.77. The Biotechnology industry median Quick Ratio is 3.60. 60 Degrees Pharmaceuticals' value of 2.85 is 20.8% below this industry median. Based on the distribution chart, 60 Degrees Pharmaceuticals ranks #810 out of 1417 companies in the Biotechnology industry, which is below the industry midpoint. Overall, 60 Degrees Pharmaceuticals has a GF Score™ of 44/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does 60 Degrees Pharmaceuticals' Quick Ratio compare to LSBCF and ACUT?
According to the Biotechnology industry distribution chart, 60 Degrees Pharmaceuticals ranks #810 out of 1417 companies for Quick Ratio. This places 60 Degrees Pharmaceuticals in the lower half of its industry. The industry median Quick Ratio is 3.60. 60 Degrees Pharmaceuticals' value of 2.85 is 20.8% below this benchmark. Historically, 60 Degrees Pharmaceuticals' own Quick Ratio has ranged from 0.02 to 6.77 over the past decade. While the company's 10-year median is 2.39 vs. the industry median of 3.60, 60 Degrees Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,417 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. 60 Degrees Pharmaceuticals's current Quick Ratio of 2.85 is 20.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on 60 Degrees Pharmaceuticals and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. 60 Degrees Pharmaceuticals's current Quick Ratio is 2.85, which is 19% above median its own 10-year median of 2.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 60 Degrees Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, 60 Degrees Pharmaceuticals (SXTP) is currently considered Modestly Undervalued. The stock's GF Value™ is $2.07, compared to a current price of $1.69 — trading 18.4% below its estimated fair value. The current Quick Ratio is 2.85, which is 19% above median its 10-year median of 2.39 and 20.8% below the Biotechnology industry median of 3.60. 60 Degrees Pharmaceuticals' overall GF Score™ is 44/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For 60 Degrees Pharmaceuticals (SXTP), the current Quick Ratio is 2.85 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is 60 Degrees Pharmaceuticals (SXTP) Overvalued in 2026?
Based on GuruFocus' analysis, 60 Degrees Pharmaceuticals stock appears to be undervalued.
The current stock price of $1.69 is trading 18.4% below its estimated GF Value™ of $2.07.
GuruFocus considers 60 Degrees Pharmaceuticals to be Modestly Undervalued.
Key valuation signals for SXTP:
Quick Ratio: 2.85 (19% above median its 10-year median of 2.39)
GF Value™: $2.07 vs. price of $1.69 (18.4% below fair value)
Industry Position: 20.8% below the Biotechnology median (#810 of 1417)
No single metric tells the full story. See the SXTP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. Currently, company's pipeline under development covers development programs for vector-borne, fungal, and viral diseases utilizing three of the Company's future products: (i) new products that contain the Arakoda regimen of Tafenoquine; (ii) new products that contain Tafenoquine; and (iii) Celgosivir and/or botanical extracts from Australian Chestnut Trees.
44GF Score
Get the complete analysis for SXTP
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SXTP has been successfully added to your 
